Record Profitability, 2026 Growth Outlook and Recorlev Patent Suit Might Change The Case For Investing In Xeris Biopharma Holdings (XERS)

Simply Wall St.00:16

In Q4 2025, Xeris Biopharma reported record revenue growth and reached profitability, and guided for over 30% growth in both adjusted EBITDA and total revenue to between US$375 million and US$390 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627457589?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-04-14 00:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627457589","market":"sg","top_or_hot":-1,"title":"Record Profitability, 2026 Growth Outlook and Recorlev Patent Suit Might Change The Case For Investing In Xeris Biopharma Holdings (XERS)","media":"Simply Wall St.","content":"<div>\n<p>In Q4 2025, Xeris Biopharma reported record revenue growth and reached profitability, and guided for over 30% growth in both adjusted EBITDA and total revenue to between US$375 million and US$390 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/record-profitability-2026-growth-outlook-and-recorlev-patent\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Record Profitability, 2026 Growth Outlook and Recorlev Patent Suit Might Change The Case For Investing In Xeris Biopharma Holdings (XERS)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecord Profitability, 2026 Growth Outlook and Recorlev Patent Suit Might Change The Case For Investing In Xeris Biopharma Holdings (XERS)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-14 00:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/record-profitability-2026-growth-outlook-and-recorlev-patent><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In Q4 2025, Xeris Biopharma reported record revenue growth and reached profitability, and guided for over 30% growth in both adjusted EBITDA and total revenue to between US$375 million and US$390 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/record-profitability-2026-growth-outlook-and-recorlev-patent\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/record-profitability-2026-growth-outlook-and-recorlev-patent","article_id":"2627457589","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/record-profitability-2026-growth-outlook-and-recorlev-patent","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627457589","pubTimestamp":1776097001,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In Q4 2025, Xeris Biopharma reported record revenue growth and reached profitability, and guided for over 30% growth in both adjusted EBITDA and total revenue to between US$375 million and US$390 million for 2026, while also filing a patent infringement lawsuit to block generic versions of Recorlev until 2040.\nThis combination of stronger financial performance and efforts to protect Recorlev’s market exclusivity could meaningfully influence expectations for the company’s future cash...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4543":"AI","BK4551":"寇图资本持仓","BK4587":"ChatGPT概念","XERS":"Xeris制药","BK4528":"SaaS概念","BK4588":"碎股","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4585":"ETF&股票定投概念","BK4023":"应用软件","AIPO":"Defiance AI and Power Infrastructure ETF","ARTY":"ISHARES FUTURE AI & TECH ETF","AGIX":"通用人工智能 ETF-AGIX","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","AI":"C3.ai, Inc."},"translate_title":"创纪录的盈利能力、2026年增长前景和Recorlev专利诉讼可能会改变投资Xeris Biopharma Holdings(XERS)的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHAT":0.62,"AI":0.62,"AGIX":0.62,"XERS":1.5,"AIYY":0.6,"ARTY":0.62,"AIPO":0.72},"content_text":"In Q4 2025, Xeris Biopharma reported record revenue growth and reached profitability, and guided for over 30% growth in both adjusted EBITDA and total revenue to between US$375 million and US$390 million for 2026, while also filing a patent infringement lawsuit to block generic versions of Recorlev until 2040. This combination of stronger financial performance and efforts to protect Recorlev’s market exclusivity could meaningfully influence expectations for the company’s future cash generation and competitive position. We’ll now examine how this record profitability and ambitious 2026 growth outlook may reshape Xeris Biopharma’s existing investment narrative and risk profile. Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.AdvertisementXeris Biopharma Holdings Investment Narrative RecapTo own Xeris Biopharma, you generally need to believe its focused endocrine portfolio can convert into durable, growing cash flows while funding future products like XP-8121. The latest step into profitability and >30% growth outlook for 2026 directly supports that belief, while the Recorlev patent lawsuit ties into the biggest current risk: concentrated dependence on a few drugs and potential generic or competitive pressure. Both developments appear highly relevant to the near term story. The most closely linked recent announcement is the USPTO Notice of Allowance for XP-8121 in December 2025, which helps reinforce Xeris’s longer term growth and differentiation case at the same time it is guiding for US$375 million to US$390 million in 2026 revenue. Together with the Recorlev patent action, this positions the company between defending today’s cash generators and building tomorrow’s, which matters if you are watching both upside catalysts and portfolio concentration risk. Yet beneath the strong 2026 guidance, there is still the very real issue of Xeris’s reliance on a small group of products that investors should be aware of... Read the full narrative on Xeris Biopharma Holdings (it's free!)Xeris Biopharma Holdings' narrative projects $440.9 million revenue and $84.8 million earnings by 2028. This requires 21.5% yearly revenue growth and a $116.8 million earnings increase from -$32.0 million today.Uncover how Xeris Biopharma Holdings' forecasts yield a $11.14 fair value, a 90% upside to its current price.Exploring Other PerspectivesXERS 1-Year Stock Price Chart Some of the lowest estimate analysts took a harsher view, despite expecting revenue to reach about US$533 million and earnings near US$71 million by 2029, reminding you that opinions can differ widely and that this new profitability and guidance could shift both the cautious and optimistic narratives.Explore 3 other fair value estimates on Xeris Biopharma Holdings - why the stock might be worth just $11.14!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Xeris Biopharma Holdings research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.Our free Xeris Biopharma Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xeris Biopharma Holdings' overall financial health at a glance.Ready To Venture Into Other Investment Styles?The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:Find 57 companies with promising cash flow potential yet trading below their fair value.Uncover the next big thing with 33 elite penny stocks that balance risk and reward.Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627457589","isCrawlerRequest":true}